• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Abstract The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. 5 Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form. -5.0% Sucrose 6.5%Sucrose 7.5%Sucrose 10%Sucrose Figure 1
    公开号:AU2013205684A1
    申请号:U2013205684
    申请日:2013-04-10
    公开日:2014-05-22
    发明作者:Yvonne VUCICA；Gary Lee WARREN
    申请人:CSL Ltd；
    IPC主号:C07K14-775
    专利说明:
    P/00/011 Regulation 3.2 AUSTRALIA Patents Act 1990 ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention Title: "RECONSTITUTED HDL FORMULATION" The following statement is a full description of this invention, including the best method of performing it known to me/us: Reconstituted HDL formulation Technical field The present invention relates to reconstituted high density lipoprotein formulations, and in particular to 5 formulations with suitable stability and biological properties for pharmaceutical use. Background art High-density lipoproteins (HDLs) form a range of lipoprotein particles found in normal serum. Mature HDL 10 particles are present in the form of a globular structure containing proteins and lipids. Within the outer layer of these particles are the more polar lipids, phospholipids and free cholesterol, all having charged groups orientated outwards, towards the aqueous environment. The more 15 hydrophobic lipids, such as esterified cholesterol and triglycerides, reside in the core of the particle. Newly formed or nascent HDL particles lack the lipid and are discoidal in shape. Protein components are embedded in the outer layer. The main protein component is apolipoprotein 20 A-I (Apo A-I) with smaller amounts of Apo A-II, Apo A-IV, Apo CIII, Apo D, Apo E and Apo J. Various other proteins reside on the HDL particle, such as lecithin-cholesterol acetyl transferase, PAF acetylhydrolase and paraoxonase. HDLs are characterized by high density (> 1.063 g/ml) and 25 small size (Stoke' s diameter = 5 to 17 nm). Efforts have been made to develop artificial HDLs that can be infused into the bloodstream of patients to mimic the biological effects of naturally-occurring HDLs. These -2 artificial particles are generally referred to as "reconstituted HDL" (rHDL) , or sometimes as HDL mimetics or synthetic HDL particles. The artificial particles contain components of the natural particles, in particular 5 Apo A-I and lipids. For example, WO 2012/000048 describes rHDL comprising Apo A-I, phosphatidylcholine (PC) and a small amount of sodium cholate. WO 2012/109162 describes rHDL comprising Apo A-I, sphingomyelin (SM) and phosphatidylglycerol (e.g. 1, 2-dipalmitoyl-sn-glycero-3 10 [hospho-rac-(1-glycerol)] (DPPG)). It is convenient for rHDL formulations to be lyophilized (freeze-dried) before use. Lyophilization is a commonly used method for preparing solid protein pharmaceuticals. However, this process generates a variety of freezing and 15 drying stresses, such as concentration of the solubilized protein, formation of ice crystals, pH changes, etc. All of these stresses can denature proteins to various degrees. Thus, stabilizers are often required in a protein formulation to protect protein stability both during 20 freezing and drying processes. In order to maintain the stability of rHDL formulations during lyophilization, stabilizers like sugars and sugar alcohols have been used. For example, US 5,089,602 discloses plasma-derived lipoproteins that are stabilized with 10% sucrose or a 25 mixture of 10% sucrose and 5% mannitol. WO 2012/000048 discloses sugar and sugar alcohol stabilizers used at a concentration from about 65 to 85 g/L of rHDL formulation (equivalent to about 6.5 to 8.5% w/w) . WO 2012/109162 discloses sucrose and mannitol as stabilizers, used in a 30 mixture at 4% w/w and 2% w/w respectively. An - 3 investigation into the manufacturing and shelf stability of rHDL was carried out in Kim et al, Biotechnology and Bioprocess Engineering 16, 785-792 (2011). Here, rHDL with an Apo A-I:soybean PC ratio of 1:150 could not be 5 sufficiently stabilized with 1 or 5% sucrose, whereas 10% sucrose was described as optimal. The rHDL formulations of these documents are intended for infusion therapy, but high sugar concentrations in infusion products may cause or exacerbate renal problems. 10 This is a particular problem in the target patient population for rHDL, because these patients are often renally impaired. Therefore, an object of the present invention was to provide alternative or improved rHDL formulations compared 15 to these previous formulations. In particular, the inventors sought stable rHDL formulations with reduced renal toxicity. This problem is solved by the formulation according to claim 1. Further preferred embodiments are defined in the 20 dependent claims. Surprisingly, it has been found that the rHDL formulation of claim 1 shows good long-term stability. By containing less lyophilization stabilizer than previous formulations, the formulation also presents less risk of renal toxicity. 25 The low lyophilization stabilizer concentration may also allow the rHDL to perform better in functional assays of rHDL function. The inventors have also found that amino acids, particularly proline, are useful lyophilization stabilizers for rHDL formulations.
    -4 Summary of the invention The invention provides an rHDL formulation comprising an apolipoprotein, a lipid and a lyophilization stabilizer, wherein the ratio between the apolipoprotein and the lipid 5 is from about 1:20 to about 1:120 (mol:mol). Preferably, the lyophilization stabilizer is present in a concentration from about 1.0% to about 6.0% (w/w of rHDL formulation), e.g. from 1.0, 1.1, 1.2 or 1.3 to 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0. This low amount of lyophilization 10 stabilizer may reduce the risk of renal toxicity. It is also particularly suitable for patients receiving contrast agents during acute coronary syndrome therapy (ACS), since these agents may compete with lyophilization stabilizer for clearance in the kidneys. In a preferred embodiment, 15 the lyophilization stabilizer is present in a concentration from about 1.0% to less than 6.0% e.g. from about 1.0% to 5.9%. Preferably the lyophilization stabilizer is present in a concentration from about 3.0 to less than 6.0%, e.g. from about 3.0 to 5.9%. More 20 preferably, the lyophilization stabilizer is present in a concentration from about 4.0 to 5.5%, particularly 4.3 to 5.3%, more particularly 4.3 to 5.0%, and most preferably 4.6 to 4.8% (w/w). Such formulations show good stability and low renal toxicity. 25 Alternatively, or in addition, it is preferred for the ratio between the apolipoprotein and the lyophilization stabilizer to be from about 1:1 to about 1:3 (w:w). In particular, the ratio between the apolipoprotein and the lyophilization stabilizer is from about 1:1 to about 1:2.4 - 5 (w:w), e.g. less than 1:2 (w:w). The inventors have found that these formulations remain stable showing few or no changes in the size distribution of lyophilized samples, even after storage for several months. However, in some s embodiments, the ratio between the apolipoprotein and the lyophilization stabilizer may be less than this, e.g. from about 1:1 to about 1:7, and in particular from about 1:1 to about 1:5 (w:w). The invention also provides an rHDL formulation comprising 10 an apolipoprotein, a lipid and a lyophilization stabilizer, wherein the lyophilization stabilizer comprises an amino acid. Preferably the amino acid is proline. The inventors have found that amino acids are good lyophilization stabilizers for rHDL formulations, 15 particularly when in a mixture with low amounts of other stabilizers. Detailed description of the invention Within the context of the present invention, the term "reconstituted HDL (rHDL) formulation" means any 20 artificially-produced lipoprotein formulation or composition that is functionally similar to, analogous to, corresponds to, or mimics, high density lipoprotein (HDL), typically present in blood plasma. rHDL formulations include within their scope "HDL mimetics" and "synthetic 25 HDL particles". Within the context of the present invention, the term "lyophilization stabilizer" means a substance that stabilizes protein during lyophilization. Such lyophilization stabilizers are well known in the art and -6 are reviewed in, for example, Wang (2000) International Journal of Pharmaceuticals 203:1-60. A preferred lyophilization stabilizer for use in the invention comprises a sugar, a sugar alcohol, an amino acid, or a 5 mixture thereof . For example, the inventors have found that disaccharides such as sucrose are particularly suitable sugars for use as the lyophilization stabilizer. Other disaccharides that may be used include fructose, trehalose, maltose and lactose. In addition to 10 disaccharides, trisaccharides like raffinose and maltotriose may be used. Larger oligosaccharides may also be suitable, e.g. maltopentaose, maltohexaose and maltoheptaose. Alternatively, monosaccharides like glucose, mannose and galactose may be used. These mono-, is di-, tri- and larger oligo-saccharides may be used either alone or in combination with each other. As noted above, lyophilization stabilizers that are sugar alcohols may also be used. These sugar alcohols may also be used either alone or in combination. A particular sugar 20 alcohol for use in the invention is mannitol. Other sugar alcohols that may be used include inositol, xylitol, galactitol, and sorbitol. Other polyols like glycerol may also be suitable. Amino acids that may be used as lyophilization stabilizers include proline, glycine, 25 serine, alanine, and lysine. Modified amino acids may also be used, for example 4-hydroxyproline, L-serine, sodium glutamate, sarcosine, and y-aminobutyric acid. The inventors have found that proline is a particularly suitable amino acid for use as a lyophilization 30 stabilizer.
    -7 In particular embodiments, the lyophilization stabilizer comprises a mixture of a sugar and a sugar alcohol. For example, a mixture of sucrose and mannitol may be used. The sugar and the sugar alcohol may be mixed in any 5 suitable ratio, e.g. from about 1:1 (w:w) to about 3:1 (w:w), and in particular about 2:1 (w:w). Ratios less than 2:1 are particularly envisaged, e.g. less than 3:2. Typically, the ratio is greater than 1:5, e.g. greater than 1:2 (w:w) . In some embodiments the formulation 10 comprises less than 4% sucrose and 2% mannitol (w/w of rHDL formulation), for example 3% sucrose and 2% mannitol. In some embodiments the formulation comprises 4% sucrose and less than 2% mannitol. In some embodiments the formulation comprises less than 4% sucrose and less than is 2% mannitol e.g. about 1.0% to 3.9% sucrose and about 1.0% to 1.9% (w/w) mannitol. In particular embodiments, the lyophilization stabilizer comprises a mixture of a sugar and an amino acid. For example, a mixture of sucrose and proline may be used. The 20 sugar and the amino acid may be mixed in any suitable ratio, e.g. from about 1:1 to about 3:1 (w:w), and in particular about 2:1 (w:w). Ratios less than 2:1 are particularly envisaged, e.g. less than 3:2 (w:w). Typically, the ratio is greater than 1:5, e.g. greater 25 than 1:2 (w:w) . Preferably the amino acid is present in a concentration of from about 1.0 to about 2.5% e.g. from 1.0, 1.2, or 1.3 to 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5% (w/w of rHDL formulation). In some embodiments the formulation comprises 1.0% sucrose and 2.2% proline, or 3.0% sucrose 30 and 1.5% proline, or 4% sucrose and 1.2% proline. The -8 amino acid may be added to the sugar to maintain an isotonic solution. Solutions with an osmolality of greater than 350 mosmol/kg are typically hypertonic, while those of less than 250 mosmol/kg are typically hypotonic. 5 Solutions with an osmolality of from 250 mosmol/kg to 350 mosmol/kg are typically isotonic. In particular embodiments, the lyophilization stabilizer comprises a mixture of a sugar alcohol and an amino acid. The lyophilization stabilizer may comprise a mixture of a 10 sugar, a sugar alcohol, and an amino acid. The apolipoprotein may be any apolipoprotein which is a functional, biologically active component of naturally occurring HDL or of a reconstituted high density lipoprotein/rHDL. Typically, the apolipoprotein is either 15 a plasma-derived or recombinant apolipoprotein such as Apo A-I, Apo A-II, Apo A-V, pro-Apo A-I or a variant such as Apo A-I Milano. Preferably, the apolipoprotein is Apo A-I. More preferably the Apo A-I is either recombinantly derived comprising a wild type sequence or the Milano 20 sequence or alternatively it is purified from human plasma. The apolipoprotein may be in the form of a biologically-active fragment of apolipoprotein. Such fragments may be naturally-occurring, chemically synthetized or recombinant. By way of example only, a 25 biologically-active fragment of Apo A-I preferably has at least 50%, 60%, 70%, 80%, 90% or 95% to 100% or even greater than 100% of the lecithin-cholesterol acyltransferase (LCAT) stimulatory activity of Apo A-I.
    - 9 In the present invention the molar ratio of apolipoprotein:lipid is typically from about 1:20 to about 1:120, and preferably from about 1:20 to about 1:100, more preferably from about 1:20 to about 1:75 (mol:mol), and in 5 particular from 1:45 to 1:65. This range includes molar ratios such as about 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, 1:85, 1:90, 1:95 and 1:100. A particularly advantageous ratio of apolipoprotein:lipid is from 1:40 to 1:65 (mol:mol). 10 This ensures that the rHDL formulation according to the present invention comprises a lipid at a level which does not cause liver toxicity. In other embodiments, the molar ratio of apolipoprotein:lipid may be in a range from about 1:80 to is about 1:120. For example, the ratio may be from 1:100 to 1:115, or from 1:105 to 1:110. In these embodiments, the molar ratio may be for example from 1:80 to 1:90, from 1:90 to 1:100, or from 1:100 to 1:110. In a preferred embodiment the rHDL formulation according to the present 20 invention comprises additionally a detergent in order to further stabilize the rHDL particles. The detergent may be any ionic (e.g. cationic, anionic, zwitterionic) detergent or non-ionic detergent, inclusive of bile acids and salts thereof, suitable for use in rHDL formulations. Ionic 25 detergents may include bile acids and salts thereof, polysorbates (e.g. PS80), 3-[(3 Cholamidopropyl) dimethylammonio] -1-propane-sulfonate (CHAPS), 3- [(3-Cholamidopropyl)dimethylammonio] -2-hydroxy 1-propanesulfonate (CHAPSO), cetyl trimethyl-ammonium 30 bromide, lauroylsarcosine, tert-octyl phenyl - 10 propanesulfonic acid and 4' -amino-7-benzamido-taurocholic acid. Bile acids are typically dihydroxylated or trihydroxylated steroids with 24 carbons, including cholic acid, s deoxycholic acid, chenodeoxycholic acid or ursodeoxycholic acid. Preferably, the detergent is a bile salt such as a cholate, deoxycholate, chenodeoxycholate or ursodeoxycholate salt. A particularly preferred detergent is sodium cholate. The concentration of the detergent, in 10 particular of sodium cholate, is preferably 0.5 to 1.5 mg/mL. The ratio between the apolipoprotein and the lyophilization stabilizer is usually adjusted so this ratio is from about 1:1 to about 1:7 (w:w). More 15 preferably, the ratio is from about 1:1 to about 1:3, in particular about 1:1.1 to about 1:2. In specific embodiments the rHDL formulations thus have ratios of 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9 or 1:2 (w:w) . It is however contemplated that for 20 particular embodiments where there are low amounts of protein (e.g. <20mg/mL) that the ratio between the apolipoprotein and the lyophilization stabilizer can be extended to as much as about 1:7 (w:w), e.g. about 1:4.5 (w:w). 25 Suitably, the apolipoprotein is at a concentration from about 5 to about 50 mg/ml. This includes 5, 8, 10, 15, 20, 25, 30, 35, 40, 45 and 50 mg/ml and any ranges between these amounts. The apolipoprotein is, preferably, at a concentration from about 25 to 45 mg/ml. In other - 11 embodiments, the apolipoprotein may be at a concentration of from about 5 to 20 mg/ml, e.g. about 8 to 12 mg/ml. The lipid may be any lipid which is a functional, biologically active component of naturally occurring HDL 5 or of reconstituted high density lipoprotein (rHDL). Such lipids include phospholipids, cholesterol, cholesterol esters, fatty acids and/or triglycerides. Preferably, the lipid is at least one charged or non-charged phospholipid or a mixture thereof. 10 In a preferred embodiment the rHDL formulation according to the present invention comprises a combination of a detergent and a non-charged phospholipid. In an alternative preferred embodiment the rHDL formulation comprises a charged phospholipid but no detergent at all. is In a further preferred embodiment the rHDL formulation comprises charged and non-charged lipids as well as a detergent. As used herein, "non-charged phospholipids", also called neutral phospholipids, are phospholipids that have a net 20 charge of about zero at physiological pH. Non-charged phospholipids may be zwitterions, although other types of net neutral phospholipids are known and may be used. "Charged phospholipids" are phospholipids that have a net charge at physiological pH. The charged phospholipid may 25 comprise a single type of charged phospholipid, or a mixture of two or more different, typically like-charged phospholipids. In some examples, the charged phospholipids are negatively charged glycophospholipids.
    - 12 The formulation according to the present invention may also comprise a mixture of different lipids, such as a mixture of several non-charged lipids or of a non-charged lipid and a charged lipid. Examples of phospholipids 5 include phosphatidylcholine (lecithin), phosphatidic acid, phosphatidylethanolamine (cephalin), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylinositol (PI) and sphinogomyelin (SM) or natural or synthetic derivatives thereof. Natural derivatives include egg io phosphatidylcholine, egg phosphatidylglycerol, soy bean phosphatidylcholine, hydrogenated soy bean phosphatidylcholine, soy bean phosphatidylglycerol, brain phosphatidylserine, sphingolipids, brain sphingomyelin, egg sphingomyelin, galactocerebroside, gangliosides, 15 cerebrosides, cephalin, cardiolipin and dicetylphospate. Synthetic derivatives include dipalmitoylphosphatidylcholine (DPPC), didecanoyl phosphatidylcholine (DDPC), dierucoylphosphatidylcholine (DEPC), dimyristoylphosphatidylcholine (DLPC), palmitoyl 20 oleoylphosphatidylcholine (PMPC), palmitoylstearoyl phosphatidylcholine (PSPC), dioleoylphosphatidyl ethanolamine (DOPE), dilauroylphosphatidylglycerol (DLPG), distearoylphosphatidylglycerol (DSPG), dioleoyl phosphatidylglycerol (DOPG), palmitoyloleoylphosphatidyl 25 glycerol (POPG), dimyrstolyphosphatidic acid (DMPA), dipalmitoylphosphatidic acid (DPPA), distearoyl phosphatidic acid (DSPA), dipalmitoylphosphatidylserine (DPPS), distearoylphosphatidylethanolamine (DSPE), di oleoylphosphatidylethanolamine (DOPE), dioleoyl 30 phosphatidylserine (DOPS), dipalmitoylsphingomyelin (DPSM) and distearoylsphingomyelin (DSSM). The phospholipid can - 13 also be a derivative or analogue of any of the above phospholipids. Best results could be obtained with phosphatidylcholine. In another embodiment the lipids in the formulation according to the present invention are 5 sphingomyelin and a negatively charged phospholipid, such as phosphatidylglycerol (e.g. DPPG). A mixture of sphingomyelin and phosphatidylglycerol (particularly DPPG) is specifically envisaged for use in the invention. In these embodiments, the sphingomyelin and the 10 phosphatidylglycerol may be present in any suitable ratio, e.g. from 90:10 to 99:1 (w:w), typically 95:5 to 98:2 and most typically 97:3. The formulation according to the present invention typically has a lyophilization stabilizer concentration is from about 1.0% to about 6.0% e.g. from 1.0, 1.1, 1.2 or 1.3% to 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0%, preferably from about 1.0% to less than 6.0%, e.g. from about 1.0% to 5.9% (w/w of rHDL formulation). Preferably from about 3.0% to less than 6.0%, e.g. from about 3.0% to 5.9%, preferably 20 from about 4.0 to 5.9%, preferably, from about 4.0% to 5.5%, preferably 4.3 to 5.3%, preferably 4.3 to 5.0%, and most preferably from 4.6 to 4.8% (w/w) and in said formulation the ratio between the apolipoprotein and the lipid is preferably from about 1:20 to about 1:75, more 25 preferably from about 1:45 to about 1:65 (mol:mol). The lyophilization stabilizer is preferably a sugar (e.g. sucrose), optionally in combination with a sugar alcohol such as mannitol or sorbitol, or an amino acid such as proline.
    - 14 In a preferred embodiment, the rHDL formulation according to the present invention has a pH in the range of 6 to 8, preferably within the range of 7 to 8. Even more preferably the pH is in the range of 7.3 to 7.7. s In a preferred embodiment of the present invention, the formulation is lyophilized. Due to the presence of lyophilization stabilizer, preferably of sucrose, sucrose and mannitol, or sucrose and proline, in combination with the apolipoprotein:lipid ratio, the lyophilisation yields 10 in a stable powder having a long shelf life. This powder may be stored, used directly or after storage as a powder or used after rehydration to form the reconstituted high density lipoprotein formulation. The invention may be used for large scale production of 15 reconstituted high density lipoprotein. The lyophilized product may be prepared for bulk preparations, or alternatively, the mixed protein/lipid solution may be apportioned in smaller containers (for example, single dose units) prior to lyophilization, and such smaller 20 units may be used as sterile unit dosage forms. The lyophilized formulation can be reconstituted in order to obtain a solution or suspension of the protein-lipid complex, that is the reconstituted high density lipoprotein. The lyophilized powder is rehydrated with an 25 aqueous solution to a suitable volume. Preferred aqueous solutions are water for injection (WFI), phosphate-buffer saline or a physiological saline solution. The mixture can be agitated to facilitate rehydration. Preferably, the reconstitution step is conducted at room temperature.
    - 15 It is well known to the person skilled in the art how to obtain a solution comprising the lipid, and the apolipoprotein, such as described in WO 2012/000048. In one preferred embodiment, the invention provides a 5 method of producing a rHDL formulation including the step of adding the lyophilization stabilizer to the solution comprising the lipid, and the apolipoprotein until a concentration of from about 1.0% to about 6.0% (w/w of rHDL formulation) is reached, e.g. from 1.0, 1.1, 1.2 or 10 1.3 to 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0. In a preferred embodiment, the lyophilization stabilizer is added until a concentration from about 1.0% to less than 6.0% e.g. from about 1.0% to 5.9% is reached. Preferably lyophilization stabilizer is added until a concentration from about 3.0 15 to less than 6.0%, e.g. from about 3.0 to 5.9% is reached. More preferably the lyophilization stabilizer is added until a concentration from about 4.0 to 5.5%, particularly 4.3 to 5.3%, more particularly 4.3 to 5.0%, and most preferably 4.6 to 4.8% (w/w) is reached. The solution may 20 already contain stabilizer. In preferred embodiments the solution additionally includes a detergent such as sodium cholate. In a preferred embodiment the rHDL formulation is manufactured by combining Apo A-I purified from plasma, with 25 phosphatidylcholine (PC) in the presence of sodium cholate and sucrose at a concentration from about 1.0% to about 6.0%, preferably from about 1.0% to less than 6.0% w/w to produce disc shaped, non-covalently associated particles (MW approximately 144 kDa).
    - 16 In particular embodiments the rHDL formulation is comprised of an Apo A-I (recombinant or purified from plasma) and phoshatidylcholine stabilized by cholate and sucrose at a concentration from about 1.0% to about 6.0% s w/w, preferably from about 1.0% to less than 6.0%. Preferably the recombinant Apo A-I comprises either a wild type sequence or the Milano sequence (which when expressed forms dimers) The lyophilized rHDL formulation of the present invention io may be formed using any method of lyophilization known in the art, including, but not limited to, freeze drying, i.e. the apolipoprotein/lipid-containing solution is subjected to freezing followed by reduced pressure evaporation. 15 The lyophilized rHDL formulations that are provided can retain substantially their original stability characteristics for at least 2, 4, 6, 8, 10, 12, 18, 24, 36 or more months. For example, lyophilized rHDL formulations stored at 2-80C or 25 OC can typically retain 20 substantially the same molecular size distribution as measured by HPLC-SEC when stored for 6 months or longer. Particular embodiments of the rHDL formulation can be stable and suitable for commercial pharmaceutical use for at least 6 months, 12 months, 18 months, 24 months, 36 25 months or even longer when stored at 2-8cC and/or room temperature. The rHDL formulation according to the present invention may be used in treating a disease, disorder or condition in a human. Suitably, the disease, disorder or condition - 17 is responsive to prophylactic or therapeutic administration of the rHDL formulation according to the present invention. Examples of such diseases, disorders or conditions include atherosclerosis; cardiovascular disease s (e.g. acute coronary syndrome (ACS) such as angina pectoris and myocardial infarction); or diseases, disorders or conditions such as diabetes that predispose to ACS; hypercholesterolaemia (e.g. elevated serum cholesterol or elevated LDL cholesterol) and 10 hypocholesterolaemia resulting from reduced levels of high-density lipoprotein (HDL), such as being symptomatic of Tangier disease. rHDL formulations according to the present invention may be administered by any route of administration known in 15 the art. Preferably, rHDL formulations are administered parenterally, such as by intravenous (IV) infusion or injection. In preferred embodiments the rHDL formulation comprises Apo A-I (recombinant or purified from plasma) which has been reconstituted to form particles suitable 20 for IV infusion. The administered dosage of the rHDL formulation may be in the range of from about 1 to about 120 mg/kg body weight. Preferably, the dosage is in the range of from about 5 to about 80 mg/kg inclusive of 8 mg/kg, 10 mg/kg, 12 mg/kg, 25 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, and 70 mg/kg dosages. Alternatively delivery can be achieved by fixed dosages of rHDL, that is, in an amount independent of patient body weight. Preferred fixed dosages include 0.1-15g, 0.5-12g, 1-10g, 2-9g, 3-8g, 4-7g or 5-6g of 30 apolipoprotein. Particularly preferred fixed dosages - 18 include 1-2g, 3-4g, 5-6g or 6-7g of apolipoprotein. Non limiting examples of specific fixed dosages include 0.25g, 0.5g, 1.0g, 1.7g, 2.0g, 3.4g, 4.0g, 5.1g, 6.0g, 6.8g and 8.Og of apolipoprotein. Accordingly, a vial preferably 5 comprises the lyophilized rHDL formulation with a protein content of 0.25g, 0.5g, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8 or 10 g per vial. More preferably the protein content is either 0.5, 1, 2, 4, 6, 8, or 10 g per vial. The invention also provides an apolipoprotein kit 10 comprising one or more unit doses of the apolipoprotein formulation disclosed herein and one or more other kit components. Suitably, the kit is for prophylactically or therapeutically treating a disease, disorder or condition is in a human, as hereinbefore described. Non-limiting examples of one or more other kit components include instructions for use; vials, containers or other storage vessels containing each of the unit doses; delivery devices such as needles, catheters, syringes, 20 tubing and the like; and/or packaging suitable for safely and conveniently storing and/or transporting the kit. Preferably the instructions for use are a label or package insert, wherein the label or package insert indicates that the apolipoprotein formulation may be used to treat a 25 disease or condition such as cardiovascular disease by administering a fixed dose amount to a human subject in need thereof. A 'package insert' refers to instructions included in commercial packages of the apolipoprotein formulations, - 19 that contains information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such apolipoprotein formations. For the purposes herein, a 'vial' refers to a container s which holds an apolipoprotein formulation. The vial may be sealed by a stopper pierceable by a syringe. Generally, the vial is formed from a glass material. The apolipoprotein formulation in the vial can be in various states including liquid, lyophilized, frozen etc. The 10 fixed dosage apolipoprotein formulation is preferably stable as turbidity is a preferred measure. A turbidity level of below about 5, 10, 15, 20, or 30 NTU can generally be considered a stable dosage apolipoprotein formulation. Turbidity measurements can be taken by 15 incubating the apolipoprotein formulations over time periods such as 0 hr, 2 hr, 4hr, 6 hr, 12 hr, 18 hr, 24 hr, 36 hr, 72 hr, 7 days and 14 days at storage temperatures such as room temperature or 2 to 8 0 C. Preferably the apolipoprotein formulation is considered to 20 be stable as a liquid when it is stored for 14 days at room temperature and exhibits a turbidity of less than about 15 NTU. The kit may facilitate administration of the apolipoprotein formulation by a health professional or 25 self-administration by a patient or caregiver. As used herein, the term "comprising" encompasses "including" as well as "consisting" e.g. a formulation or a component of a formulation that is described as "comprising" X may consist exclusively of X or may include - 20 something additional e.g. X + Y. The term "about" in relation to a numerical value x means, for example, x+10%. The word "substantially" does not exclude "completely" 5 e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention. Where the invention provides a process involving multiple 10 sequential steps, the invention can also provide a process involving less than the total number of steps. The different steps can be performed at very different times by different people in different places (e.g. in different countries). 15 Unless specifically stated, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the 20 combination may be combined with the third component, etc. Various embodiments of the invention are described herein. It will be appreciated that the features specified in each embodiment may be combined with other specified features, to provide further embodiments. In particular, embodiments 25 highlighted herein as being suitable, typical or preferred may be combined with each other (except when they are mutually exclusive).
    - 21 BRIEF DESCRIPTION OF DRAWINGS: Figure 1: Molecular size distribution of formulations containing 5 to 10% w/w sucrose. Figure 2A: Direct comparison of molecular size 5 distribution of formulations containing 4 and 7.5% w/w sucrose. Figure 2B: Molecular size distribution of formulations containing 1, 2, 3, 4 and 7.5% (w/w) sucrose. Figure 2C: Molecular size distribution of formulations 10 containing sucrose and proline and 7.5% sucrose. Figures 3A and 3B: LCAT activity for 4 to 10% w/w sucrose formulations. Figure 3C: LCAT activity for 1, 2, 3, 4 and 7.5% w/w sucrose formulations. 15 Figure 3D: LCAT activity for formulations containing sucrose and proline. Figure 4A to 4B: Impact of sucrose concentration on cholesterol efflux. Figure 4C: Impact of formulations containing sucrose and 20 proline on cholesterol efflux. Figures 5A to 5H: Turbidity of formulations with different sucrose concentrations and formulations containing sucrose and proline. Figure 6: Picture of lyo cakes with different sucrose 25 concentration.
    - 22 Figure 7: Picture of lyo cakes with different sucrose concentrations and sucrose and proline. Examples Example 1: Preparation of the samples s To make the samples for the following experiments, sodium cholate (New Zealand Pharmaceuticals) was dissolved in buffer (10 mM NaCl, 1 mM EDTA, 10 mM TRIS, pH 8.0) and stirred until clear. Soybean phosphatidylcholine (Phospholipid GmbH) was added to an appropriate volume of 10 the cholate and stirred for 16 h at room temperature. The Apo A-I solution was diluted to a protein concentration of 9.0 mg/mL (determined by OD280) with 10 mM NaCl and mixed with an appropriate volume of the lipid solution to obtain protein to lipid ratio in the range of 1:45 to 1:65. The 15 mixture was stirred at 2-8 0 C for 30 min to 16 h. The HDL mimetics were prepared by cholate dialysis using 1% sucrose as a diafiltration buffer. The eluate was concentrated to a protein concentration of 33 to 38 g protein /L. Sucrose was added to obtain the desired 20 concentration (1%, 2%, 3%, 4%, 5%, 6.5%, 7%, 10% w/w). The pH of the solution was adjusted, with 0.2 M NaOH to pH 7.50 + 0.1 after which WFI (water for injection) was added to obtain a protein concentration of 30 mg/mL. The final formulations were then sterile filtered through a 0.2 + 25 0.1 ym filter and filled into 100 mL glass vials at 1.7 g protein per vial and lyophilized. In some formulations proline was added to the desired concentration. Proline maintains an isotonic formulation.
    - 23 Example 2: Molecular size distribution Particle formation was determined using HPLC-SEC and assessed by the molecular size distribution of the various s formulations. Little difference was observed for formulations containing 5-10% w/w sucrose in the final formulation (Figure 1), indicating that formulations containing 5% w/w sucrose did not affect particle stability after reconstitution. Figure 1 shows a complete 10 chromatogram of (1) internal control, 2: 5% w/w sucrose, 3: 6.5% w/w sucrose, 4: 7.5% w/w sucrose and 5: 10% w/w sucrose. In addition a direct comparison between a 7.5% w/w sucrose formulation and 4% w/w sucrose formulation demonstrated 15 that these formulations exhibit a similar molecular size distribution (Figure 2A). Figures 2B and 2C show the results for sucrose concentrations 1, 2, 3, and 4% (w/w) and formulations comprising sucrose and proline. 20 All tested formulations are stable. The sucrose content of 4 to 7.5% w/w was optimum and did not affect the particle stability after reconstitution. Example 3: LCAT activation A measure of the effectiveness of the rHDL particles in 25 various formulations was determined by measuring the LCAT activity. HDL particles are capable of sequestering cholesterol from plaques formed along artery walls or - 24 cells by interaction with the ATP-binding cassette transporter Al (ABCAl). Lecithin-cholesterol acyltransferase (LCAT) , a plasma enzyme converts the free cholesterol into cholesteryl ester (a more hydrophobic 5 form of cholesterol) , which is then sequestered into the core of the HDL particle before being transported to the liver to be metabolized. If the sucrose content in the final formulation affected the efficacy of the rHDL particle, LCAT activity would decrease. 10 Figures 3A and 3B show LCAT activity for 4-10% w/w sucrose formulations. Figure 3C shows LCAT activity for 1-4% w/w sucrose formulations. Very little difference is seen in LCAT activity when the sucrose ranges from 5-10% w/w in the final formulation (Figure 3A), however a slight 15 decreasing trend is evident when the sucrose is further reduced to 4% w/w (Figure 3B). Figure 3D shows LCAT activity for formulations comprising sucrose and proline. No apparent trend in LCAT activity is observed for formulations containing sucrose and proline. Thus the 20 efficacy of the HDL particle in sucrose/proline formulations is maintained. Example 4: Cholesterol efflux Reverse cholesterol transport (RCT) is a pathway by which accumulated cholesterol is transported from the vessel 2S wall to the liver for excretion. Cells efflux free cholesterol to lipid-poor Apo A-I via the ABCA1 pathway. The cholesterol efflux assay measures the capacity of HDL to accept cholesterol released from cells. It is anticipated that if sucrose content affected particle - 25 formation and/or integrity, differences would affect cholesterol efflux. Figures 4A and 4B show that as sucrose concentration decreases from 7.5% w/w to 4% w/w the cholesterol efflux 5 increased. No apparent difference in cholesterol efflux was observed between the proline containing formulations and the 7.5% sucrose formulation (Figure 4C). Example 5: Turbidity The term turbidity is used to describe the cloudiness or 10 haze in a solution. Strictly, turbidity arises from the multiple scattering events of visible light by elements present in the solution. Since turbidity arises from the net scattered light, it depends on the sample path length, protein concentration and size of the 15 protein/aggregates/particles. Given that all reduced sucrose formulations contained the same protein concentration upon reconstitution and were measured with the same path length, differences in turbidity can be attributed to differences in the size and/or number of 20 protein/aggregates/particles resulting from the various sucrose formulations. Formulations containing 4 - 10% w/w sucrose produced similar turbid solutions upon reconstitution (Figures 5A & 5B). Sucrose concentrations of less than 4% showed 25 increased turbidity (Figures 5E and 5G). Based on turbidity, sucrose concentrations of 4% (w/w) and above are optimum. Relative increases in the turbidity of a solution upon - 26 storage, is often cited as an indication of aggregation in protein biopharmaceuticals. Figures SC, SD, 5F and SH show that little to no increase in turbidity are seen upon storage in liquid form, thereby indicating stability of 5 the particles. Example 6: Lyo cake appearance Sucrose formulations with 4% w/w and 7.5% w/w sucrose produced the most stable lyo cakes (Figure 6). Sucrose formulations with 1 to 4% w/w, and formulations 10 containing sucrose and proline, also produced stable lyo cakes (Figure 7).
    权利要求:
    Claims (36)
    [1] 1. A reconstituted high density lipoprotein (rHDL) formulation comprising an apolipoprotein, a lipid and a lyophilization stabilizer, wherein the ratio between the 5 apolipoprotein and the lipid is from about 1:20 to about 1:120 (mol:mol) and the lyophilization stabilizer is present in a concentration from about 1.0% to less than
    [2] 6.0% (w/w of rHDL formulation). 2. The rHDL formulation according to claim 1, wherein io the ratio between the apolipoprotein and the lyophilization stabilizer is from about 1:1 (w:w) to about 1:7 (w:w). 3. The rHDL formulation according to claim 2, wherein the ratio between the apolipoprotein and the 15 lyophilization stabilizer is from about 1:1 (w:w) to about 1:3 (w:w). 4. The rHDL formulation according to claim 3, wherein the ratio between the apolipoprotein and the lyophilization stabilizer is from about 1:1 (w:w) to about 20 1:2.4 (w:w). 5. The rHDL formulation according to claim 4, wherein the ratio between the apolipoprotein and the lyophilization stabilizer is from about 1:1 (w:w) to less than 1:2 (w:w). 25 6. The rHDL formulation according to any of the preceding claims, wherein the lyophilization stabilizer is - 28 present in a concentration of from about 1.0 to 5.9% (w/w).
    [3] 7. The rHDL formulation according to any of the preceding claims, wherein the lyophilization stabilizer is 5 present in a concentration from about 3.0 to 5.9% (w/w).
    [4] 8. The rHDL formulation according to any of the preceding claims, wherein the lyophilization stabilizer is present in a concentration from about 4.0 to 5.5% (w/w).
    [5] 9. The rHDL formulation according to claim 8, wherein 10 the lyophilization stabilizer is present in a concentration of 4.3 to 5.3% (w/w).
    [6] 10. The rHDL formulation according to claim 9, wherein the lyophilization stabilizer is present in a concentration of 4.6 to 4.8% (w/w). 15 11. The rHDL formulation according to any of the preceding claims, wherein the lyophilization stabilizer comprises a sugar, a sugar alcohol, an amino acid or a mixture thereof.
    [7] 12. The rHDL formulation according to claim 11, wherein 20 the sugar is a monosaccharide, disaccharide or trisaccharide.
    [8] 13. The rHDL formulation according to claim 12, wherein the sugar is a disaccharide.
    [9] 14. The rHDL formulation according to claim 13, wherein 25 the disaccharide is sucrose, fructose, trehalose, maltose or lactose. - 29 15. The rHDL formulation according to claim 14, wherein the disaccharide is sucrose.
    [10] 16. The rHDL formulation according to any of claims 11-15, wherein the sugar alcohol is mannitol, inositol, 5 xylitol, galactitol or sorbitol.
    [11] 17. The rHDL formulation according to claim 16, wherein the sugar alcohol is mannitol.
    [12] 18. The rHDL formulation according to any of claims 11 to 17, wherein the amino acid is proline, glycine, serine, 10 alanine, lysine, 4-hydroxyproline, L-serine, sodium glutamate, lysine hydrochloride, sarcosine, or y-aminobutyric acid.
    [13] 19. The rHDL formulation according to claim 18, wherein the amino acid is proline. 15 20. The rHDL formulation according to any of claims 11 to 15, wherein the lyophilization stabilizer comprises a sugar.
    [14] 21. The rHDL formulation according to any of claims 11 and 16-17, wherein the lyophilization stabilizer comprises 20 a sugar alcohol.
    [15] 22. The rHDL formulation according to any of claims 11 and 18-19, wherein the lyophilization stabilizer comprises an amino acid.
    [16] 23. The rHDL formulation according to any of claims 25 11-17, wherein the lyophilization stabilizer comprises a mixture of a sugar and a sugar alcohol. - 30 24. The rHDL formulation according to claim 23, wherein the sugar and the sugar alcohol are mixed in a ratio from about 1:1 (w:w) to about 3:1 (w:w).
    [17] 25. The rHDL formulation according to claim 26, wherein 5 the sugar and the sugar alcohol are mixed in a ratio less than 2:1 (w:w).
    [18] 26. The rHDL formulation according to any of claims 11-15 and 18-19, wherein the lyophilization stabilizer comprises a mixture of a sugar and an amino acid. 10 27. The rHDL formulation according to claim 26, wherein the lyophilization stabilizer comprises 1% sucrose and 2.2% proline (w/w).
    [19] 28. The rHDL formulation according to claim 26, wherein the lyophilization stabilizer comprises 3% sucrose and is 1.5% proline (w/w).
    [20] 29. The rHDL formulation according to claim 26, wherein the lyophilization stabilizer comprises 4% sucrose and 1.2% proline (w/w).
    [21] 30. The rHDL formulation according to any of claims 11, 20 and 16-19, wherein the lyophilization stabilizer comprises a mixture of a sugar alcohol and an amino acid.
    [22] 31. The rHDL formulation according to any of the preceding claims, wherein the formulation comprises additionally a detergent. 25 32. The rHDL formulation according to claim 31, wherein the detergent comprises sodium cholate. - 31 33. The rHDL formulation according to any of the preceding claims, wherein the ratio between the apolipoprotein and the lipid is from about 1:20 to about 1:100 (mol:mol). s 34. The rHDL formulation according to any of the preceding claims, wherein the concentration of the apolipoprotein is from about 5 to about 50 mg/ml.
    [23] 35. The rHDL formulation according to any of the preceding claims, wherein the apolipoprotein comprises 10 apolipoprotein A-I (Apo A-I).
    [24] 36. The rHDL formulation according to claim 35, wherein the Apo A-I is purified from plasma.
    [25] 37. The rHDL formulation according to claim 35, wherein the Apo A-I is recombinant, preferably comprising wild i5 type or the Milano sequence.
    [26] 38. The rHDL formulation according to any of the preceding claims, wherein the apolipoprotein is a fragment of apolipoprotein.
    [27] 39. The rHDL formulation according to any of the 20 preceding claims, wherein the lipid comprises at least one charged or non-charged phospholipid or a mixt~ire thereof, preferably a phosphatidylcholine.
    [28] 40. The rHDL formulation according to any of the preceding claims, wherein the apolipoprotein is Apo A-I 25 purified from plasma, the lipid is phosphatidylcholine, the lyophilization stabilizer is sucrose and the formulation further comprises sodium cholate detergent. - 32 41. The rHDL formulation according to claim 40, wherein the ratio between the apolipoprotein and the lipid is from 1:45 to 1:65 (mol:mol); the lyophilization stabilizer is present in a concentration of 4.6 to 4.8% (w/w); and the s sodium cholate is present at a concentration of 0.5 to 1.5 mg/mL.
    [29] 42. The rHDL formulation according to any of the preceding claims, wherein the apolipoprotein is recombinant Apo A-I, the lipid is a mixture of 10 sphingomyelin and phosphatidylglycerol and the lyophilization stabilizer is a mixture of sucrose and mannitol.
    [30] 43. The rHDL formulation according to claim 42, wherein the ratio between the apolipoprotein and the lipid is from 15 1:80 to 1:120 (mol:mol), the sphingomyelin and the phosphatidylglycerol are present in a ratio from 90:10 to 99:1 (w:w), and the sucrose and the mannitol are mixed in a ratio less than 2:1 (w:w).
    [31] 44. The rHDL formulation according to any of the 20 preceding claims, wherein the formulation has a pH in the range of 6 to 8.
    [32] 45. A rHDL formulation according to any of the preceding claims, wherein the formulation is lyophilized.
    [33] 46. A vial comprising the lyophilized rHDL formulation 25 according to claim 45, wherein the protein content is 1, 2, 4, 6, 8, or 10 g per vial.
    [34] 47. A method of producing a rHDL formulation comprising an apolipoprotein, a lipid, and a lyophilization - 33 stabilizer, the ratio between apolipoprotein and the lipid being from 1:20 to 1:120 (mol:mol), said method including the step of adding the lyophilization stabilizer to the solution comprising the lipid, and the apolipoprotein 5 until a concentration from about 1.0% to less than 6.0% (w/w) is reached.
    [35] 48. A rHDL formulation according to any one of claims 1 to 45 for use in treating a disease, disorder or condition in a human. 10 49. A rHDL formulation for use according to claim 48, wherein the disease, disorder or condition includes cardiovascular disease, hypercholesterolaemia or hypocholesterolaemia.
    [36] 50. A rHDL formulation for use according to claim 49, is wherein the disease, disorder or condition includes acute coronary syndrome (ACS) , atherosclerosis, angina pectoris and myocardial infarction.
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2013205684B2|2015-08-20|Reconstituted hdl formulation
    TWI531388B|2016-05-01|Lipoprotein formulation and production method thereof
    US20070254832A1|2007-11-01|Methods for the treatment of macular degeneration and related eye conditions
    WO2011138802A1|2011-11-10|Injection solution
    JP2017128586A|2017-07-27|Dosage regime for apolipoprotein formulations
    DK2916857T3|2019-04-15|RECONSTITUTED HDL FORMULATION
    US20070197442A1|2007-08-23|Methods for the Treatment of Macular Degeneration and Related Eye Conditions
    NZ624558B2|2015-12-01|Dosage regime for apolipoprotein formulations
    同族专利:
    公开号 | 公开日
    JP2015535263A|2015-12-10|
    US9925236B2|2018-03-27|
    AU2013205684B2|2015-08-20|
    BR112015009748B1|2021-04-27|
    US20200397859A1|2020-12-24|
    NZ631131A|2015-12-24|
    RU2015120808A|2016-12-20|
    RU2669568C2|2018-10-12|
    CN108057023A|2018-05-22|
    IL238504D0|2015-06-30|
    US20140221272A1|2014-08-07|
    BR112015009748A2|2017-07-11|
    EP3502131A1|2019-06-26|
    IL238504A|2018-02-28|
    CN104755096A|2015-07-01|
    KR102263810B1|2021-06-15|
    MX364587B|2019-05-02|
    MX2015004546A|2015-07-14|
    US10603355B2|2020-03-31|
    US9125943B2|2015-09-08|
    KR20150079947A|2015-07-08|
    WO2014066943A1|2014-05-08|
    EP2916857B1|2019-01-16|
    SG11201503083UA|2015-05-28|
    EP2916857A1|2015-09-16|
    JP6340372B2|2018-06-06|
    PL2916857T3|2019-06-28|
    EP2916857A4|2016-05-25|
    US20150306176A1|2015-10-29|
    CA2889785A1|2014-05-08|
    CN104755096B|2017-10-13|
    CN108057023B|2022-02-08|
    HK1212599A1|2016-06-17|
    US20190015476A1|2019-01-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CA1335077C|1988-02-08|1995-04-04|Henri Isliker|Process for the manufacture of apolipoproteins from human blood plasma or serum|
    US5652339A|1993-12-31|1997-07-29|Rotkreuzstiftung Zentrallaboratorium|Method of producing reconstituted lipoproteins|
    CA2460787A1|2001-09-28|2003-04-03|Esperion Therapeutics, Inc.|Prevention and treatment of restenosis by local administration of drug|
    US20040038891A1|2002-05-17|2004-02-26|Bisgaier Charles L.|Methods and compositions for the treatment of ischemic reperfusion|
    PE20050438A1|2003-10-20|2005-06-14|Esperion Therapeutics Inc|PHARMACEUTICAL FORMULAS, METHODS AND DOSING REGIMES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES|
    US20070254832A1|2006-02-17|2007-11-01|Pressler Milton L|Methods for the treatment of macular degeneration and related eye conditions|
    KR100992488B1|2006-12-29|2010-11-05|주식회사 녹십자|METHOD OF PURIFYING ApoA-I AND METHOD OF PRODUCING RECONSTITUTED HIGH DENSITY LIPOPROTEIN BY USING THE PURIFIED ApoA-I|
    CA2694854C|2007-08-17|2016-09-27|Csl Behring Gmbh|Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i|
    WO2010057203A2|2008-11-17|2010-05-20|The Board Of Regents Of The University Of Texas System|Hdl particles for delivery of nucleic acids|
    SG186386A1|2010-06-30|2013-01-30|Csl Ltd|A reconstituted high density lipoprotein formulation and production method thereof|
    PT2673296T|2011-02-07|2019-01-31|Cerenis Therapeutics Holding Sa|Lipoprotein complexes and manufacturing and uses thereof|
    US9125943B2|2012-11-02|2015-09-08|Csl Limited|Reconstituted HDL formulation|SG186386A1|2010-06-30|2013-01-30|Csl Ltd|A reconstituted high density lipoprotein formulation and production method thereof|
    US9125943B2|2012-11-02|2015-09-08|Csl Limited|Reconstituted HDL formulation|
    NZ631116A|2013-06-05|2018-07-27|Csl Ltd|Process for preparing apolipoprotein a-i |
    WO2015017888A1|2013-08-08|2015-02-12|Csl Limited|Contaminant removal method|
    EP3490579A1|2016-07-27|2019-06-05|Hartis-Pharma SA|Therapeutic combinations to treat red blood cell disorders|
    JP2019533705A|2016-11-10|2019-11-21|シーエスエル、リミテッド|Reconstructed high-density lipoprotein therapy for myocardial infarction|
    CN112546201A|2019-09-26|2021-03-26|中国科学院生物物理研究所|Application of artificial lipoprotein particle apoA-IV fat body in treatment and/or prevention of diabetes|
    法律状态:
    2015-12-17| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    US201261721771P| true| 2012-11-02|2012-11-02||
    US61/721,771||2012-11-02||
    EP13153903||2013-02-04||
    EP13153903.3||2013-02-04||CA2889785A| CA2889785A1|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    PL13851610T| PL2916857T3|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    NZ631131A| NZ631131A|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    KR1020157014530A| KR102263810B1|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    JP2015539998A| JP6340372B2|2012-11-02|2013-10-31|Reconstituted HDL formulation|
    MX2015004546A| MX364587B|2012-11-02|2013-10-31|Reconstituted hdl formulation.|
    RU2015120808A| RU2669568C2|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    SG11201503083UA| SG11201503083UA|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    TR2019/05244T| TR201905244T4|2012-11-02|2013-10-31|HDL formulation prepared by reconstitution.|
    PCT/AU2013/001260| WO2014066943A1|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    DK13851610.9T| DK2916857T3|2012-11-02|2013-10-31|RECONSTITUTED HDL FORMULATION|
    US14/439,094| US9925236B2|2012-11-02|2013-10-31|Reconstituted HDL formulation|
    ES13851610T| ES2719275T3|2012-11-02|2013-10-31|Formulation of reconstituted high density lipoprotein|
    EP19151328.2A| EP3502131A1|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    CN201380057007.0A| CN104755096B|2012-11-02|2013-10-31|The HDL preparatons of reconstruct|
    BR112015009748-0A| BR112015009748B1|2012-11-02|2013-10-31|FORMULATION OF RECONSTITUTED HDL, ITS PRODUCTION METHOD AND ITS USE|
    EP13851610.9A| EP2916857B1|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    HUE13851610A| HUE042620T2|2012-11-02|2013-10-31|Reconstituted hdl formulation|
    CN201711141045.0A| CN108057023B|2012-11-02|2013-10-31|Reconstituted HDL formulation|
    IL238504A| IL238504A|2012-11-02|2015-04-28|Reconstituted hdl formulation|
    HK16100504.1A| HK1212599A1|2012-11-02|2016-01-18|Reconstituted hdl formulation hdl|
    US15/894,397| US10603355B2|2012-11-02|2018-02-12|Reconstructed HDL formulation|
    US16/826,585| US20200397859A1|2012-11-02|2020-03-23|Reconstituted HDL Formulation|
    [返回顶部]